Literature DB >> 7109851

Comparison of the interaction of antineoplastic aminoanthraquinone analogs with DNA using competitive fluorescence polarization.

J Roboz, C L Richardson, J F Holland.   

Abstract

1,4-dihydroxy-5-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione one (NSC 287836) and 1,4-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione diacetate (NSC 287513) have shown activity against solid tumors and are now in Phase I clinical trials. Fluorescence polarization was used to determine the extent of inhibition of the binding of acridine orange to DNA (Richardson, Boboz, Holland, Res. Comm. Chem. Pathol. Pharmac. 27, 497, 1980). Displacement of 50% of acridine orange from calf thymus DNA was obtained with 0.18 micro M of NSC 287836 while 0.52 micro M of NSC 287513 was needed to displace an equivalent amount of acridine orange. NSC 287513 showed preference for polynucleotides of high adenine + thymine content while NSC 287836 did not. Analogs lacking both hydroxyethylaminoethyl-amino side chains did not displace acridine orange.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7109851     DOI: 10.1016/0024-3205(82)90396-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  DNA sequence specificity of mitoxantrone.

Authors:  C Panousis; D R Phillips
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

2.  Detection and quantification of mitoxantrone in human organs. A case report.

Authors:  J Roboz; P A Paciucci; D Silides; J Greaves; J F Holland
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 3.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 4.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

5.  Development of mitoxantrone.

Authors:  R J White; F E Durr
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids.

Authors:  J Kapuscinski; Z Darzynkiewicz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.